phase 1 study of anti-pd-l1 durvalumab plus gefitinib in tki-naïve patients with egfr-mutant nsclc
Published 8 years ago • 237 plays • Length 2:12Download video MP4
Download video MP3
Similar videos
-
2:07
dr. creelan discusses results of anti-pd-l1 antibody in combination with gefitinib in nsclc
-
20:35
tki-resistant egfr-mutant nsclc
-
2:36
atezolizumab with erlotinib in combination treatment for egfr mutant nsclc
-
1:44
pd-l1 testing in first-line treatment of nsclc
-
3:54
adding gefitinib to conventional therapy of patients with egfr-mutant non-small cell lung cancer
-
3:16
phase 1b trial of durvalumab plus tremelimumab for advanced non-small cell lung cancer
-
1:33
neoadjuvant egfr tki trials in nsclc
-
4:10
combination of medi0680, an anti-pd-1 antibody, with durvalumab, an anti-pd-l1 antibody
-
4:50
tatton: phase 1b trial of azd9291 for egfr-mutant lung cancer
-
2:56
non-tki-based treatment options for egfr-mutant lung cancer
-
1:52
egfr-mutant lung cancer cells have a unique response to anti-pd-l1 antibodies
-
3:31
osimertinib plus gefitinib for treatment of egfr-mutated non-small cell lung cancer
-
2:16
dr. rotow on results of a phase 1/2 trial with osimertinib/gefitinib in egfr-mutant nsclc
-
3:50
testing the safety and efficacy of the pd-l1 antibody durvalumab
-
2:20
osimertinib in advanced non–small-cell lung cancer
-
7:10
toward a cure: chemotherapy plus tki in egfr-mutant nsclc
-
1:19
immune checkpoint inhibitors, durvalumab plus tremelimumab, for non-small cell lung cancer
-
5:01
illuminate: durvalumab, tremelimumab, and chemotherapy in egfr mutant nsclc | dr. ankur punia| crsf
-
7:46
egfr and pd-l1 testing in locally advanced nsclc